One in six American men will develop prostate cancer. It is the most common cancer after skin cancer, and the second biggest cancer killer for men. Two Israeli scientists at the Weizmann Institute in Israel promise an almost miraculous cure, now in clinical trials at New York’s Sloan Kettering Cancer Center. It is the culmination of 20 years of basic research by plant scientist Avigdor Scherz and cancer researcher Yoram Saloman.
Professor Scherz took a naturally occurring form of chlorophyll from aquatic bacteria:
…chemically modified by Prof. Scherz’s lab at Weizmann to fit the team’s pharmaceutical needs. Once the photosensitized drug is injected, it meets up with the second crucial element in this therapy—light—at the targeted tumor site… from highly focused fiber-optic lasers that have been inserted near the tumor. As the chlorophyll absorbs the light, it can then interact with the third component in the process—oxygen—to produce oxygen radicals. This interaction initiates a fast cascade of pathophysiological events that cause instantaneous closing of the blood vessels leading to the tumor, followed by oxygen and nutrient deprivation at the tumor site, as well as other active processes that kill tumor cells. In 24 to 48 hours, the tumor undergoes complete necrosis.
The treatment, called vascular-targeted photodynamic therapy or VTP is a one-time 20 to 30-minute procedure. There have been no side effects in urination or sexual function.
The Israeli team foresees applications for breast, ovary, lung and pancreas tumors. The latter has no effective treatment to date and has been a tragic death sentence.